Fennec Pharmaceuticals (FENC) Cash from Financing Activities (2010 - 2025)
Fennec Pharmaceuticals (FENC) posted Cash from Financing Activities of $20.8 million for Q4 2025, up 1089.42% on a QoQ basis from $1.7 million in Q3 2025, and up 270.35% year-over-year from $5.6 million in Q4 2024.
Fennec Pharmaceuticals (FENC) Cash from Financing Activities (2010 - 2025) Analysis & Trends
Fennec Pharmaceuticals' Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $20.8 million for Q4 2025.
- Quarterly Cash from Financing Activities rose 270.35% year-over-year to $20.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22.6 million (up 266.19% YoY) and the FY2025 annual result came in at $22.6 million, up 266.19% from the prior year.
- Cash from Financing Activities was $20.8 million for Q4 2025 at Fennec Pharmaceuticals, up from $1.7 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $20.8 million in Q4 2025 and bottomed at -$12.2 million in Q4 2024.
- A 5-year average of $2.1 million and a median of $201000.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities jumped 8140.0% — and 2024, when it slumped 686.53%.
- Fennec Pharmaceuticals' Cash from Financing Activities stood at $10000.0 in 2021, then soared by 8140.0% to $824000.0 in 2022, then soared by 595.39% to $5.7 million in 2023, then plunged by 313.12% to -$12.2 million in 2024, then surged by 270.35% to $20.8 million in 2025.
- Business Quant data shows FENC's Cash from Financing Activities at $20.8 million in Q4 2025, $1.7 million in Q3 2025, and -$284000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 238.74 Mn |
| 10 | Fennec Pharmaceuticals | 287.77 Mn | 250.98 Mn | 12.01 Mn | 20.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 20.80 Mn |
| Dec 31, 2025 | 20.80 Mn |
| Sep 30, 2025 | 1.75 Mn |
| Sep 30, 2025 | 1.75 Mn |
| Jun 30, 2025 | -284,000.00 |
| Jun 30, 2025 | -284,000.00 |
| Mar 31, 2025 | 359,000.00 |
| Mar 31, 2025 | 359,000.00 |
| Dec 31, 2024 | -12.21 Mn |
| Dec 31, 2024 | -12.21 Mn |
| Sep 30, 2024 | -528,000.00 |
| Sep 30, 2024 | -528,000.00 |
| Jun 30, 2024 | 257,000.00 |
| Jun 30, 2024 | 257,000.00 |
| Mar 31, 2024 | -1.13 Mn |
| Mar 31, 2024 | -1.13 Mn |
| Dec 31, 2023 | 5.73 Mn |
| Dec 31, 2023 | 5.73 Mn |
| Sep 30, 2023 | 201,000.00 |
| Sep 30, 2023 | 201,000.00 |